Upregulation of HSPA8 and SEC61A1 affected hepatocarcinogenesis, identifying HSPA8 and SEC61A1 as potential therapeutic targets in liver cancer [39,40,41]. This evidence concerns the gene SEC61A1 and liver cancer.